formaldehyde

IPOL

IPV

IPOL is used for primary and booster vaccination of infants, children and adults to protect against infection with Type 1, Type 2 and Type 3 polioviruses causing poliomyelitis.

Influenza vaccine (brand names may vary year to year)

Influenza types in the vaccine usually change season to season

The influenza vaccine is given to protect against influenza in children older than six months of age and adults. The World Health Organization monitors influenza illness throughout the year and make recommendations on which three influenza types are likely to cause the most illness in the northern and in the southern hemisphere during their respective influenza seasons. Vaccine ingredients are specific to the brand of influenza vaccine they are associated with and may vary to year. Specific information on ingredients in the vaccines use each season can be found on the individual vaccine datasheets.

Act-HIB™

Haemophillus influenzae type b (Hib)

Act-HIB™ is used for primary and booster vaccination of infants and children up to their 5th birthday to protect against disease caused by Haemophilus influenzae type b.The vaccine is also used for primary vaccination of children aged 5 years of age and over and adults with some chronic medical conditions. Act-HIB™ is licensed for use in infants and children 2 months to 5 years of age. It is used out of licensure in children 5 years of age and over and adults as there is no alternative vaccine available in New Zealand for these age groups. When children/individuals are older than the age to which the vaccine is licensed, use will be outside of current licensure. No safety concerns are expected for use in older age groups.

ADT™ Booster

Td

ADT™ Booster is used for primary and booster vaccination of children 7 years of age and over and adults to protect against tetanus and diphtheria. An alternative vaccine called Boostrix®, which protects against tetanus, diphtheria and pertussis (whooping cough), can be substituted for one, two or all three doses of the primary vaccinations in these age groups. Both ADT™ Booster and Boostrix® are licensed as booster vaccines. They are used for primary vaccination out of licensure as there is no alternative primary vaccination strength vaccine available in New Zealand for these age groups. When the vaccine is used for a primary vaccination course, use will be outside of current licensure. No safety concerns are expected with use in these circumstances.

Infanrix®-IPV

DTaP-IPV

Infanrix®-IPV is used for primary and booster vaccination of infants and children up to their 7th birthday to protect against diphtheria, tetanus, pertussis and poliomyelitis.

Infanrix®-hexa

DTaP-IPV-HepB/Hib

Infanrix®-hexa is used for primary and booster vaccination of infants and children up to their 5th birthday to protect against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type b.

 

Boostrix®

Tdap

Boostrix® is used for booster vaccination of adolescents aged 11 years and pregnant women between 28-38 weeks gestation to protect against diphtheria, tetanus and pertussis (whooping cough).

*After immunisation protection against pertussis takes up to two weeks to develop. Whilst immunisation between 38-40 weeks gestation is still safe for mother and baby later immunisation means the newborn may still be exposed to the disease by their mother on delivery and/or during the first two weeks of life. The PHARMAC decision to limit funded Boostrix® to 28-38 weeks gestation maximises the benefit of immunisation against pertussis whilst being accountable for the use of public funds. Pregnant women can choose to purchase Boostrix® privately after 38 weeks gestation or at any time after delivery.

Boostrix® is licensed for use in children 10 years of age and over and adults as a booster vaccine. Boostrix® can be used, out of licensure in children from 7 years of age and adults, for one or all three doses of a primary course of tetanus and diphtheria vaccination, so as to provide protection from pertussis (whooping cough). There is no alternative vaccine that provides protection from pertussis available in New Zealand for this age group. 

When children are younger than the age to which the vaccine is licensed, and when the vaccine is used for a primary vaccination course, use will be outside of current licensure and parents/guardians/individuals must be fully informed of this. There are not expected to be any safety concerns for use in these circumstances.

Subscribe to RSS - formaldehyde